- AMAb90655 - Atlas Antibodies RBM3 antibody

Submitted references Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.

Olofsson SE, Nodin B, Gaber A, Eberhard J, Uhlén M, Jirström K, Jerkeman M
PloS one 2015;10(3):e0121300

Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.

Florianova L, Xu B, Traboulsi S, Elmansi H, Tanguay S, Aprikian A, Kassouf W, Brimo F
World journal of surgical oncology 2015 Nov 14;13:317

Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods.

Dubois L, Andersson K, Asplund A, Björkelund H
BMC research notes 2013 Dec 18;6:542

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.

Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström PU
BMC urology 2013 Apr 8;13:17

Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods

Dubois L, Andersson K, Asplund A, Björkelund H
BMC Research Notes 2013 ;6(1):542

High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.

Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström K
Diagnostic pathology 2012 Jul 17;7:82

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.

Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström K
Diagnostic pathology 2011 Sep 28;6:91

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K
Journal of translational medicine 2011 Jul 21;9:114

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.

Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson LB, Påhlman S, Jirström K, Uhlen M
Proteomics. Clinical applications 2011 Dec;5(11-12):624-35

RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.

Ehlén Å, Nodin B, Rexhepaj E, Brändstedt J, Uhlén M, Alvarado-Kristensson M, Pontén F, Brennan DJ, Jirström K
Translational oncology 2011 Aug;4(4):212-21

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K
Journal of translational medicine 2010 Aug 20;8:78

No comments: Submit comment

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunofluorescence staining of U-2 OS cells using the anti-RBM3 monoclonal antibody, showing specific staining in the nucleoplasm in green. Microtubule- and nuclear probes are visualized in red and blue, respectively (where available).
Sample type: HUMAN

Enhanced validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Orthogonal validation
Main image
Experimental details: Immunohistochemistry analysis in human tonsil and liver tissues using AMAb90655 antibody. Corresponding RBM3 RNA-seq data are presented for the same tissues.
Sample type: HUMAN
Orthogonal method: Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues.

: Show more

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human breast cancer shows moderate nuclear positivity in tumour cells.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human colorectal tumour shows moderate nuclear positivity in cancer cells.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human prostate tumour shows moderate to strong nuclear positivity in tumour cells.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human tonsil shows moderate nuclear positivity in lymphoid cells, mainly in germinal centra.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human rectum shows moderate nuclear positivity in glandular cells.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human breast cancer shows moderate nuclear positivity in tumor cells.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human colorectal cancer shows weak to moderate nuclear positivity in a subset of tumor cells.

Supportive validation

Submitted by: Atlas Antibodies (provider)
Main image
Experimental details: Immunohistochemical staining of human liver shows no positivity in hepatocytes as expected.

AMAb90655

Antibody data